IN THE CLAIMS

1-40 (canceled)

41. (currently amended) A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of insulin and insulin, a PKCα inhibitor, wherein the PKCα inhibitor consists of the myristoylated peptide of SEQ ID NO: 1, and at least one additional agent acting in synergy with said insulin to induce or accelerate the healing process of a skin wound, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition.

Claims 42-112 (canceled)

113. (new) A composition comprising insulin and a PKCa inhibitor of SEQ ID NO: 1.